comparemela.com

Latest Breaking News On - N alzcur se0010133785 - Page 1 : comparemela.com

AlzeCure participates at Penser Market on May 25

AlzeCure Pharma AB , a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both. | May 16, 2023

Nasdaq first north premier growth marketAlzecure pharma ab publ stock exchangePress releaseN alzcur se0010133785

AlzeCure presents new data on the anti-inflammatory effects of its TrkA-NAM pain project at IASP 2022

AlzeCure Pharma AB , a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both. | September 22, 2022

Pontus forsellAlzecure pharmaAnti inflammatory effectsSmall molecule negative allosteric modulatorsAlzecure pharma ab publ stock exchangePress releaseN alzcur se0010133785

AlzeCure gets approval to start Phase II clinical trial with non-opioid pain project ACD440

AlzeCure Pharma AB , a pharmaceutical company that develops a broad portfolio of small molecule drug candidates for diseases affecting the central nervous system, with projects in both. | May 25, 2022

Nasdaq first north premier growth marketAlzecure pharma ab publ stock exchangePress releaseN alzcur se0010133785

AlzeCure gets two NeuroRestore abstracts accepted to Alzheimer s conference

AlzeCure Pharma AB , a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both. | March 22, 2022

Pontus forsellCristina parrado fernJohan sandinNeurotrophin trkAlzheimer researchResults fromSingle ascending dose studyPositive modulatorNeurotrophin trk receptorsSwedish meetingAlzecure pharma ab publ stock exchangePress releaseN alzcur se0010133785

vimarsana © 2020. All Rights Reserved.